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Background: Due to potential advantages, human adenoviral vectors have been evaluated pre-clinically as
recombinant vaccine vectors against several cancers and infectious diseases, including human immunodeficiency
virus (HIV) infection. The V3 loop of HIV-1 glycoprotein 120 (gp120) contains important neutralizing epitopes and
plays key roles in HIV entry and infectivity.
Methods: In order to investigate the humoral immune response development against portions of the V3 loop, we
sought to generate four versions of adenovirus (Ad)-based V3 vectors by incorporating four different antigen inserts
into the hypervariable region 1 (HVR1) of human adenovirus type 5 (hAd5) hexon. The strategy whereby antigens
are incorporated within the adenovirus capsid is known as the “Antigen Capsid-Incorporation” strategy.
Results: Of the four recombinant vectors, Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3 had the capability to present
heterologous antigens on capsid surface, while maintaining low viral particle to infectious particle (VP/IP) ratios. The
VP/IP ratios indicated both high viability and stability of these two vectors, as well as the possibility that V3 epitopes
on these two vectors could be presented to immune system. Furthermore, both Ad-HVR1-lgs-His6-V3 and Ad-HVR1-
long-V3 could, to some extent escape the neutralization by anti-adenovirus polyclonal antibody (PAb), but rather
not the immunity by anti-gp120 (902) monoclonal antibody (MAb). The neutralization assay together with the
whole virus enzyme-linked immunosorbent assay (ELISA) suggested that these two vectors could present V3
epitopes similar to the natural V3 presence in native HIV virions. However, subsequent mice immunizations clearly
showed that only Ad-HVR1-lgs-His6-V3 elicited strong humoral immune response against V3. Isotype ELISAs
identified IgG2a and IgG2b as the dominant IgG isotypes, while IgG1 comprised the minority.
Conclusions: Our findings demonstrated that human adenovirus (hAd) vectors which present HIV antigen via the
“Antigen Capsid-Incorporation” strategy could successfully elicit antigen-specific humoral immune responses, which
could potentially open an avenue for the development of Ad-based HIV V3 vaccines.
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Viral vectors have been engineered for the development of
vaccines and gene therapy vectors against types of infectious
diseases and cancers [1-3]. Adenovirus (Ad) vectors had
accounted for 23.3% of gene-therapy clinical trials by year
2012 [4]. The broad utility of Ad vectors is due to two major
advantages. Firstly, the Ad genome is easily manipulated,
making replication-defective Ad capable of propagation in
complementing cells. Secondly, Ad can infect a broad range
of cells, transferring encoded genes and leading to abundant
transgene expressions [1,5]. hAd5 has been employed for
transgene therapies, whereby encoded genes were inserted
in the early regions (E), and expressed under promoters
[6-8]. However, 50-90% of normal adults have hAd5 pre-
existing immunity (PEI), which immune-clears hAd5
and hampers high levels of transgene-specific immune
responses [1,9,10]. The “Antigen Capsid-Incorporation”
strategy is one effort that allows vectors to potentially
escape the anti-hAd5 immunity and induce robust spe-
cific humoral immune responses by presenting heterol-
ogous antigens on hAd5 capsid [11-16].
The well-defined V3 machinery in HIV entry and the
fact that V3 is the primary target for neutralizing anti-
bodies [17], have led to major focuses in inhibiting HIV
binding/entry via targeting V3 domains. These include
developing anti-HIV drugs [18,19], evaluating antiviral
activities of multivalent anionic porphyrins [20], bacter-
ial lipopolysaccharide [21], or Epap-1 [22], and the anti-
V3 immune response investigations [23-26]. Early study
demonstrated that the cyclic V3-loop-related HIV-1 con-
jugate vaccines elicited neutralizing antibodies [27]. Two
V3-based vaccine phase I trials were completed in the
1990s. Of which, the HIV-1 Octameric V3 Peptide
Vaccine (Clinical Trials.gov Identifier: NCT00000775)
was proven to be safe and able to induce humoral and
cell-mediated immune responses [28]. The other vaccine
(HIV-1 C4-V3 Polyvalent Peptide) trial (Clinical Trials.
gov Identifier: NCT00001060) was also demonstrated
safe and immunogenic [29]. Some V3-specific neutralizing
monoclonal antibodies (MAbs) have been well character-
ized. Anti-gp120 (902) MAb [30] for instance, fully neu-
tralizes HIV-1 LAV strain. 447-52D MAb [31] and
HGN194 MAb [32] are more examples representing po-
tent and broadly neutralizing MAbs against V3. Notably,
the Shimada group reported that Ad5 vector presenting
V3 in HVR5 induced cell-mediated V3-specific immune
responses in mice with pre-existing immunity against Ad5
[33]. All data highlight the importance of V3 as target for
broadly neutralizing antibodies and vaccine development.
Our work is a logical extension of other V3-based
vaccine strategies and our ability to insert the ELDKWAS
sequence of HIV gp41 in HVR1 of Ad5 hexon using the
“Antigen Capsid-Incorporation” strategy [34]. Our ques
tion regarding anti-V3 immune response is, could hAd5vector properly display V3 in the HVR1 region, and
trigger efficient V3-specific humoral immune response?
Characterizations were undertaken to understand the
stability and viability of recombinant hAd5 vectors, the V3
display capability on adenoviral capsid, as well as the V3
antigenicity and immunogenicity.
Results
Ad vector construction and characterization
Four versions of recombinant Ad5 vectors were con-
structed and rescued. They were Ad-HVR1-lgs-His6-V3,
Ad-HVR1-V3, Ad-HVR1-long-V3 and Ad-HVR1-lgs-V3-
His6-lgs (Figure 1A). All vectors contain the same short V3
sequence (rgpgrafvti, HIV-1 strain IIIB, located in aa 318–
327, also named I10 peptide [35]), two of which also con-
tain spacers prior to or after the I10 peptide (Figure 1A).
Physical titers and infectious titers were determined, lead-
ing to the calculation of VP/IP ratios. A normal VP/IP ratio
of unmodified Ad ranges from ~10-30 [34]. We observed
normal to slightly increased VP/IP ratios for Ad-HVR1-
lgs-His6-V3 (ratio of 37) and Ad-HVR1-long-V3 (ratio of
63), when compared to the Ad vector (ratio of 31) (Table 1).
These ratios suggested that the insertion of lgs-His6-V3 or
long-V3 had minimal effects on the stability and infectivity
of Ad vectors. Contrarily, the insertion of a short peptide
V3 or lgs-V3-His6-lgs in the HVR1 strongly affects the sta-
bility and infectivity of vectors Ad-HVR1-V3 (ratio of
3.5 × 105) or Ad-HVR1-lgs-V3-His6-lgs (ratio of 1.9 × 10
5)
(Table 1).
Western-blot was used to validate whether all V3 inser-
tions could be displayed in the Ad5 HVR1. Whereby, anti-
penta-His MAb, anti-gp120 (902) MAb (targeting a
portion of the V3 epitope, rgpgrafvti) and anti-V3 IIIB
MAb (targeting a portion of the V3 epitope, inctrpnntkkririq)
were used respectively to detect His6 and V3. Results
showed that anti-penta-His MAb detected higher levels of
His6 in Ad-HVR1-lgs-His6-V3 than in Ad-HVR1-lgs-V3-
His6-lgs (Figure 1B). V3 was detected by anti-gp120 (902)
MAb both in Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-
V3, rather than in Ad-HVR1-V3 or Ad-HVR1-lgs-V3-
His6-lgs (Figure 1C). Anti-V3 IIIB MAb detected V3
display only in the vector Ad-HVR1-long-V3 (Figure 1D),
since only Ad-HVR1-long-V3 contains the specific V3
epitope to anti-V3 IIIB MAb (Figure 1A). The above data
suggested that Ad-HVR1-lgs-His6-V3 retained both His6-
specific and V3-specific antigenicity, and Ad-HVR1-long-
V3 possessed V3-specific antigenicity.
V3 could be properly exposed on Ad surface
ELISA can detect antigens without denaturing their ad-
vanced structure. By virtue of this advantage, we sought
to investigate whether the four versions of V3 antigens
and His6 could be exposed on the Ad hexon surface, in
a way similar to the native formation of corresponding
Figure 1 Construction and validation of four versions of hAd5-based V3 vectors. A) Construction schematic of four versions of hAd5-based
V3 vectors. Four V3 antigens (His-V3, V3, long-V3 and V3-His) were genetically inserted into the HVR1 locale of Ad hexon, using the strategy of
“Antigen Capsid-Incorporation”. The E1 region of all four vectors was replaced with GFP-Luc. B) After the vector construction and rescue, four
vectors were validated for His presentation via western-blot analysis, with the use of anti-penta-His MAb. Line 1, Ad-HVR1-lgs-His6-V3; line 2,
Ad-HVR1-V3; line 3, Ad-HVR1-long-V3 and line 4, Ad-HVR1-lgs-V3-His6-lgs. C) V3 presentation was also validated via western-blot analysis, with the
use of anti-gp120 (902) MAb. The vector order was the same as the arrangement in Figure 1B. D) Anti-IIIB-V3-21 MAb was also used to validate
the V3 presentation in the vectors. The vector order was the same as the arrangement in Figure 1B.
Table 1 Virological properties of vectors
Modified vectors VP Infectious Particles (IP) VP/IP
Ad 3.1 × 1012 VP/ml 1.0 × 1011 IP/ml 31
Ad-HVR1-lgs-His6-V3 3.0 × 10
12 VP/ml 7.9× 1010 IP/ml 37
Ad-HVR1-V3 1.4 × 1012 VP/ml 4.0 × 106 IP/ml 3.5 × 105
Ad-HVR1-long-V3 1.9 × 1012 VP/ml 3.0 × 1010 IP/ml 63
Ad-HVR1-lgs-V3-His6-lgs 5.5 × 10
11 VP/ml 2.8 × 106 IP/ml 1.9 × 105
All vectors are serotype and hexon 5-based.
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anti-penta-His MAb, with higher levels in the vector Ad-
HVR1-lgs-His6-V3, and much lower levels in the vector
Ad-HVR1-lgs-V3-His6-lgs (Figure 2A). Anti-gp120 (902)
MAb recognized V3 in both vectors Ad-HVR1-lgs-His6-V3
and Ad-HVR1-long-V3, whereby the latter showed higher
binding capacity (Figure 2B). We speculated that vectors
Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3 could prop-
erly expose V3 on Ad hexon surface in a configuration
similar to the native V3 formation. Ad-HVR1-lgs-His6-V3
could also properly display His6 on the Ad surface.
V3 in Ad5 HVR1 could be neutralized by a V3-specific
antibody
To confirm that our vectors present V3 in the most na-































Figure 2 Evaluation of both the His and V3 exposure capabilities on t
Whole virus ELISA was employed for this purpose. In this method, four vers
various concentrations, starting from 4.5 × 109 VP/well, and serially diluted
exposure was evaluated separately in the vectors: Ad (diamond), Ad-HVR1-
circle) and Ad-HVR1-lgs-V3-His6-lgs (blank circle). B) V3 exposure was evaluate
in Figure 2A. The values were expressed as the means from two replicates.antibodies in an in vivo system, we performed in vitro
neutralization analyses with gp120 (902) MAb. Statis-
tical analyses comparing any single V3-presenting Ad
vector between the antibody-treatment groups and vec-
tor only group illustrated that there were significant
differences, when the antibody was diluted at 1:500 and
1:1,000, as p < 0.001 and p < 0.01, respectively, which
suggested that both V3-presenting Ad vectors were
neutralized with anti-gp120 (902) MAb (Figure 3A).
The neutralization ratios illustrated that Ad-HVR1-
long-V3 were much higher neutralized (Figure 3A).
Analyses comparing the Ad vector between any
antibody-treatment group and the vector only group il-
lustrated no significance, suggesting that Ad vector was
not neutralized with the HIV antibody (Figure 3A).
These data confirmed that Ad-HVR1-lgs-His6-V3 and0.07 0.02 0.004
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Figure 3 Neutralization of three Ad vectors by anti-gp120 (902) MAb or anti-Ad PAb. A) To determine whether the V3-presenting vectors
could be neutralized by the anti-gp120 (902) MAb, MAb was diluted into three working concentrations (1:500, 1:1,000 and 1:5,000) and incubated
with Ad (negative control), Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3, respectively. Then the mixtures were added onto HeLa cells, followed by
incubation for 2 hours. The infectious titer was 5 IP/cell. Samples were harvested at 24 hours post-infection (h.p.i.) and subjected to luciferase
signal quantification by Luciferase Assay System Kit (Promega). The data were presented as neutralization ratios. B) To determine whether the
V3-presenting vectors and Ad vector could be neutralized by the anti-Ad PAb, PAb was diluted into three working concentrations (1:2,000, 1:4,000
and 1:20,000), and incubated with Ad, Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3, respectively. Samples were harvested at 24 h.p.i. and subjected
for measurement of luciferase signal, and the data were presented as neutralization ratios. The values were expressed as the mean ± standard
deviation, representing five independent replicates.
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tive V3 configuration, at least in the anti-gp120 (902)
MAb binding site.
As system control, we performed neutralization ana-
lyses with anti-Ad polyclonal antibody (PAb) to deter-
mine whether the two V3-presenting vectors could be
neutralized. Statistical analyses comparing any single
vector between the antibody-treatment groups and vec-
tor only group illustrated that there were significant
differences, only when antibody was diluted at 1:2,000,
as p < 0.001, which suggested that all the three vectors
were neutralized with the anti-Ad PAb, with Ad neu-
tralized the most (Figure 3B).Mice immunization triggered V3-specific binding
antibodies
The “prime-boost” regimen was employed with Ad vec-
tor as control to highlight the potential specific immune
responses triggered by V3. The 2-week intervals between
prime and boost or between injection and bleeding
(Figure 4A) were sufficient enough to trigger antigen
specific binding antibodies [34,36].
All sera from post-boost bleeding were first analyzed
with V3 peptide, using an isotype ELISA kit to detect
three isotypes (IgG1, IgG2a and IgG2b). As predicted,
the sera from the Ad group showed baseline signals for
all tested isotypes (Figure 4B, C and D). Compared to






































































Figure 4 (See legend on next page.)
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Figure 4 Induction of V3-specific humoral immune response after immunization. A) Schematic of “prime-boost” regimen in C57BL/6 mice.
Mice were injected with Ad, Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3, respectively. The solid lines with arrow denote the time of prime and
boost, the dotted lines with arrow denote the time of bleeding post injection. B) Sera-based isotype ELISA was employed to determine the levels
of V3-specific IgG1 isotype induced in the sera post-boost with vectors Ad, Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3. C) Sera-based isotype ELISA
was employed to determine the levels of V3-specific IgG2a isotype induced in the sera post-boost with vectors Ad, Ad-HVR1-lgs-His6-V3 and
Ad-HVR1-long-V3. D) Sera-based isotype ELISA was employed to determine the levels of V3-specific IgG2b isotype induced in the sera post-boost
with vectors Ad, Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3. The values were expressed as the mean ± standard deviation, representing eight
independent replicates.
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significance regarding the presence of IgG1, since p >
0.05 (Figure 4B); but the Ad-HVR1-lgs-His6-V3 group
did show significant signals with respect to both IgG2a
(Figure 4C) and IgG2b (Figure 4D). Statistical analyses
demonstrated in the IgG2a ELISA that the p values (com-
parison between Ad-HVR1-lgs-His6-V3 and Ad groups)
corresponding to the sera dilutions ranging from 40× to
320× were <0.0001, 0.0027, 0.0478 and 0.2011, respect-
ively. Statistical analyses also demonstrated in the IgG2b
ELISA that the p values corresponding to the sera dilu-
tions ranging from 40× to 320× were <0.0001, 0.0003,
0.0049 and 0.0262, respectively. The above two sets of
statistical analyses together with the OD450 nm values
suggested that Ad-HVR1-lgs-His6-V3 triggered higher
levels of V3-specific IgG2b response than the V3-specific
IgG2a response. Another group (Ad-HVR1-long-V3)
showed slightly higher signals in IgG1 (Figure 4B), IgG2a
(Figure 4C) and IgG2b (Figure 4D), when compared to
the Ad group. Statistical analyses showed no significance
between groups of Ad-HVR1-long-V3 and Ad. The long-
V3 peptide was also employed in the sera-based ELISA,
which confirmed that Ad-HVR1-long-V3 triggered slightly
higher binding antibodies without significance compared
to the Ad group (data not shown).
Discussion
The “Antigen Capsid-Incorporation” strategy is advanta-
geous compared to transgene expression because it allows
immune boosting of a given antigen after further adminis-
tration [1,3,34]. Our unpublished findings are that hAd5
could accommodate insertions of up to 57 amino acids in
HVR2, up to 77 amino acids in HVR5, and up to 80 amino
acids within HVR1. We demonstrated the hAd5 with
multivalent incorporation of ELDKWAS within HVR1
and His6 within HVR2 or HVR5 [34]. This study utilized
hAd5 with the “Antigen Capsid-Incorporation” strategy to
generate V3-based HIV-1 vaccine, due to the structure
and dominant immunogenicity of V3. V3 contains con-
served domains like I10 peptide targeted by cross-clade
neutralizing antibodies (NAbs) [37]. This provides a blue-
print for designing V3-based vaccines that could elicit
cross-clade NAbs. We generated hAd5-based vectors
displaying the I10 peptide in HVR1 of hexon, with Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3 showing nor-
mal VP/IP ratios (Table 1). The Shimada group generated
a hAd5-based vector (Ad-V3GFP) carrying the I10 peptide
in HVR5 of hexon, but failed in detecting V3 display [33].
The V3 detection in our Ad-HVR1-V3 vector also failed
(Figures 1C and 2B), which might be related to improper
I10 peptide folding. We speculated that a longer V3 pep-
tide or V3 peptide linked with spacers might help the V3
display. Western-blot detected V3 in Ad-HVR1-lgs-His6-
V3 and Ad-HVR1-long-V3, but not in Ad-HVR1-lgs-
V3-His6-lgs (Figure 1C, D). Similarly, whole virus ELISA
detected high V3 signal both in Ad-HVR1-lgs-His6-V3
and Ad-HVR1-long-V3, but not in Ad-HVR1-lgs-V3-
His6-lgs (Figure 2B). The above data suggested that longer
peptide may help in V3 exposure and antigenicity; a
proper spacer-linked peptide may also help V3 exposure
and antigenicity, but it might depend on the spacer link-
age sites. The importance of introducing proper spacers
to the V3 peptide will be further investigated via cryo-
electron microscopy analysis. Hence, we were the first
to not only generate hAd5-based V3 vectors by inser-
tion in HVR1, but also detect V3 exposure on hAd5
capsid.
Only specific antibody triggered by a given antigen,
which has mostly similar structural arrangement to the
native configuration of the same antigen, can efficiently
target and function on certain infectious pathogens. In
this aspect, we need to evaluate the V3 configuration on
hAd5 capsid. Neutralization assay illustrated that both
V3-presenting vectors were neutralized by the anti-
gp120 (902) MAb (Figure 3A). This supported data from
the whole virus ELISA that the anti-gp120 (902) MAb
bound to Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3
(Figure 2B). These data suggested that both vectors Ad-
HVR1-lgs-His6-V3 and Ad-HVR1-long-V3 could display
V3 configuration similar to the native V3 structure. Ad5-
specific dominant NAbs appear to be directed largely
against the hexon HVRs [38-40]. HVR1 is the largest loop
among all the HVRs. However, exchanging just HVR1-
HVR3 is insufficient to completely circumvent Ad5 pre-
immunity [40]. Based on these facts, our neutralization
results with the anti-Ad PAb could mean that since Ad
contains native hexon, it was maximally neutralized.
Whereas, the V3-presenting vectors lack a portion of
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Therefore, the V3-presenting vectors were neutralized to a
lesser degree (Figure 3B), which could possibly contribute
to Ad5 pre-immunity being moderately circumvented.
The I10 peptide is well known as an H-2Dd restricted
CD8+ CTL specific epitope [41,42], but it also activates spe-
cific humoral immune responses [43]. Our immunization
assays illustrated that V3-specific binding antibodies were
significantly triggered by Ad-HVR1-lgs-His6-V3, rather than
Ad-HVR1-long-V3, with IgG2a and IgG2b as the dominant
isotypes (Figure 4). This indicated that spacer-linked V3
peptide might help present V3 outward to facilitate the im-
munological recognition, leading to the enhanced V3 im-
munogenicity when V3 is within HVR1 of Ad5 hexon. And
this indication is consistent with previous findings that
spacer-linked peptides incorporated into adenovirus hexon
protein further improved peptide specific immunogenicity
[33,44,45]. Th1 cells activate the down-regulation of IgG1
and up-regulation of IgG2a [46]; Th2 cells up-regulate
IgG1 or IgE, but down-regulate other subtypes [47]; while
Tregs stimulate productions of IgG2b or IgA [48]. Our re-
sults regarding IgG isotype switching suggested that Th1
and Tregs possibly contribute to the V3-specific IgG2a and
IgG2b productions, in the mouse model. The investigation
of V3-specific binding antibodies is the focus of this paper.
We would investigate the V3-specific CD8+ CTL response
in the future with class I MHC/I10 peptide tetramer.
Since the mice immunization triggered high magnitudes
of V3-specific binding antibodies, we would transition
Ad-HVR1-lgs-His6-V3 to other animal models for more
stringent evaluations. Guinea pig and rabbit models have
been employed to investigate NAbs against HIV [49-51].
The well-conserved “gpgr” motif in the V3 of Ad-HVR1-
lgs-His6-V3 is critical for HIV neutralization [52], and is
highly recognized by 447-52D MAb [53]. The compara-
tively conserved “pgrafvti” motif in the V3 of Ad-HVR1-
lgs-His6-V3 is highly recognized by anti-gp120 (902)
MAb. 447-52D MAb neutralizes a subset of clade B
viruses (~45%) [53]. Anti-gp120 (902) MAb neutralizes
the majority of HIV-1 clade B strains [30,54]. Therefore,
we proposed that Ad-HVR1-lgs-His6-V3 might elicit
NAbs against V3 in guinea pig or rabbit models; and
immunization with Ad-HVR1-lgs-His6-V3 might protect
against some HIV-1 clade B strains. However, a study
showed that the epitope targeted by anti-gp120 (902)
MAb may be partially masked, which would impair the
neutralizing abilities [55]. The V3 masking in its native
configuration on HIV virion is no small task to conquer.
Therefore, more studies are needed to overcome this
potential hurdle.
Conclusions
Overall, this study demonstrated that Ad-HVR1-lgs-His6-
V3 using the “Antigen Capsid-Incorporation” strategycould not only correctly display the V3 of HIV-1 gp120,
but also effectively trigger V3-specific humoral immune
responses. This “proof-of-concept” Ad-HVR1-lgs-His6-V3
with the above concepts will be our next focuses for devel-
oping optimal Ad-based V3 vaccine candidates.
Methods
Construction of recombinant Ad5 vectors
To construct four versions of Ad5-based recombinant
viral vectors displaying V3 of HIV-1 gp120, four DNA
fragments (lgs-His6-V3, V3, long-V3 and lgs-V3-His6-lgs)
were synthesized and sub-cloned into HVR1 (a locale
replaced from amino acids 139 to 144) of shuttle plasmid
H5/pH5S [45]. The resulting plasmids HVR1-lgs-His6-V3/
pH5S, HVR1-V3/pH5S, HVR1-long-V3/pH5S and HVR1-
lgs-V3-His6-lgs/pH5S were digested with EcoRI and PmeI.
These resulting fragments containing the homologous re-
combination regions and the hexon genes were recom-
bined through homologous recombination with a SwaI-
digested Ad5 backbone lacking the hexon gene, pAd5/
ΔH5 [56]. The recombination was performed in Escheri-
chia coli BJ5183 (Stratagene, CA), leading to the identifi-
cation of positive vector clones, respectively. The E1
regions of all four V3-presenting vectors and Ad vector
control were replaced with GFP and luciferase as previ-
ously described [45].
Rescue, purification and titration of recombinant
Ad5 vectors
To rescue vectors, the recombinant adenoviral genomes
were digested with PacI, and transfected with PolyJet (Sig-
naGen Laboratories) into the Ad5-E1-expressing HEK293
cells. Multi-step large-scale propagations of recombinant
Ad5 vectors were performed after the vectors were res-
cued. To purify the rescued vectors, two-step cesium
chloride ultracentrifugation was employed, followed by
dialysis against 1x PBS containing 10% glycerol. To titrate
the purified vectors, physical titers, expressed as viral
particles (VPs) per ml were measured using absorbance at
260 nm. The infectious particles (IPs) per ml were deter-
mined by TCID50 assay [34].
Western blot
To analyze both the His6 and V3 presentations on viral
capsid, recombinant vectors were boiled and resolved on
SDS-PAGE gels, followed by transfer and blocking on
PVDF membranes. Blotting was performed with anti-
penta-His MAb (1:2,000; Qiagen, CA), anti-gp120 (902)
MAb (1:1,000; NIH AIDS Research & Reference Reagent
Program: 522) [30] and anti-IIIB-V3-21 MAb (1:500;
NIH AIDS Research & Reference Reagent Program:
1725), respectively, followed by secondary incubation
with HRP-conjugated goat anti-mouse antibody (1:5,000;
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3’3’-diaminobenzidine tablets (Sigma-Aldrich, MO) [34].
Mice immunizations
Mice immunizations with vectors (Ad, Ad-HVR1-lgs-
His6-V3 and Ad-HVR1-long-V3) were performed to de-
termine the V3-specific immunogenicity. Female C57BL/6
mice (6–8 weeks) were intramuscularly immunized with
corresponding vector (1 × 1010 VP/mouse) at each time-
point, with a two-week interval between prime and boost.
The University of Alabama at Birmingham Institutional
Animal Use and Care Committee approved the use of
mice as described herein under the approved protocol
number 101109272.
Whole virus ELISAs and sera-based isotype ELISAs
The whole virus ELISAs were performed as described else-
where [34], in order to investigate the exposure of V3 and
His6 on surface of capsid. Briefly, different amounts of
vectors were immobilized and blocked. The immobilized
vectors were incubated with anti-penta-His MAb (1:2,000)
and anti-gp120 (902) MAb (1:2,000) separately, followed
by incubation with the HRP-conjugated goat anti-mouse
antibody (1:5,000). ELISAs were developed with the SIG-
MAFAST OPD peroxidase substrate (Sigma-Aldrich, MO)
and measured at OD 450 nm.
Sera-based IgG isotype ELISAs were performed to de-
termine the magnitude of V3-specific humoral responses
and relative isotype development. Briefly, 10 μM V3 pep-
tide (RGPGRAFVTINLEEEDDD) or long-V3 peptide
(INCTRPNNTKKRIRIQ) was coated as above. Sera post-
boost were sequentially diluted and incubated for 2 hours.
Then goat anti-mouse isotypes, IgG1, IgG2a and IgG2b
(1:1,000; Sigma-Aldrich, MO) were incubated, followed by
incubation with HRP-conjugated donkey anti-goat anti-
body (1:5,000). Then ELISAs were measured as above.
Neutralization assay
To determine whether V3-presenting Ad5 vectors could be
neutralized by both the anti-gp120 (902) MAb and anti-
adenovirus PAb, HeLa cells were seeded and incubated in
6-well plates. Anti-gp120 (902) MAb (stock at 6.4 μg/ml)
was diluted into final working dilutions (1:500, 1:1,000 and
1:5,000). Anti-adenovirus PAb was diluted into final work-
ing dilutions (1:2,000, 1:4,000 and 1:20,000). Vectors (Ad,
Ad-HVR1-lgs-His6-V3 and Ad-HVR1-long-V3) were di-
luted at 5 IP/cell. Diluted antibodies and vectors were co-
incubated for 30 minutes at 37°C. Mixtures were then
added to relative wells, followed by 2-hour incubation.
Thereafter, complete culture medium was added to form a
final 1 ml/well volume. The group of vectors without anti-
body treatment was considered positive control regarding
the luciferase expression. Cells at 24 hours post-infection
were harvested in Reporter Lysis Buffer (Promega), andluciferase expressions were quantified on the B12
Luminometer (Berthold Detection Systems) by using the
Luciferase Reporter 1000 Assay System (Promega). Data
of each vector were presented as neutralization ratios,
which were the resultants of luciferase signals of one vec-
tor in positive control group divided by the signals of the
same vector in individual antibody treatment groups.
Statistical analyses
Descriptive statistics, such as means and standard devia-
tions, were computed for study variables of interest.
Comparisons were performed using analysis of variance
followed by the Tukey-Kramer multiple comparisons
test. Statistical analyses were performed using SAS. Stat-
istical significance was defined as p < 0.05.
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